Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Opdivo · 1 trial · 1 indication
evaluate the overall response rate of patients with mUM treated with TTF in combination with nivolumab and ipilimumab.
Evaluate the safety of TTF in combination with nivolumab and ipilimumab (Number of patients who developed grade 3 treatment-related adverse events as assessed by CTCAE v5)
| Arm | Type | Description |
|---|---|---|
| TTF Plus Chemotherapy | EXPERIMENTAL | Novacure Optune with Opdivo and Yervoy |
| Name | Type | Description |
|---|---|---|
| Novocure Optune | DEVICE | Novacure Optune with Opdivo and Yervoy |
| Opdivo | DRUG | Novacure Optune with Opdivo and Yervoy |
| Yervoy | DRUG | Novacure Optune with Opdivo and Yervoy |
Inclusion Criteria: 1. Patient has histologically or cytologically confirmed metastatic uveal melanoma with predominant liver involvement 2. Age 18 years or older and willing and able to provide informed consent 3. WOCBP must have a negative serum pregnancy test documented with 72 hours of first ad...
Opdivo is being studied for use in metastatic uveal melanoma. It is an investigational small molecule being evaluated in combination with nivolumab and ipilimumab. The drug is in Phase 1 clinical development for this indication, and the completed trial enrolled 10 patients in the United States.
Opdivo targets the PD-1 receptor, a protein on immune cells that helps regulate immune responses. By blocking PD-1, Opdivo is designed to enhance the immune system's ability to fight cancer cells. In the context of uveal melanoma, it is being tested in combination with other agents to potentially improve treatment outcomes.
Opdivo is being developed by NovoCure Limited, a company traded on the NASDAQ under the ticker symbol NVCR. The company is conducting clinical research on Opdivo for the treatment of metastatic uveal melanoma, with the drug currently in Phase 1 development.
Opdivo is in Phase 1 clinical development for metastatic uveal melanoma. It is an investigational drug, meaning it has not been approved by regulatory authorities. The completed Phase 1 trial, NCT05004025, evaluated the drug in combination with nivolumab and ipilimumab in 10 patients.
Opdivo has one completed clinical trial, NCT05004025, titled "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma." This Phase 1 trial enrolled 10 patients in the United States and was not randomized or double-blinded, and it did not use a control group.
Opdivo is the brand name for nivolumab, a PD-1 inhibitor. In the clinical trial for uveal melanoma, Opdivo (nivolumab) is being tested in combination with ipilimumab, another immunotherapy drug. The trial combines these agents to evaluate their safety and efficacy in metastatic uveal melanoma.